Cytokinetics EBITDA Margin 2010-2024 | CYTK

Cytokinetics ebitda margin for the quarter ending June 30, 2024 was -16433.33%.

  • Cytokinetics average ebitda margin for 2023 was -4208.97%, a 1700.78% increase from 2022.
  • Cytokinetics average ebitda margin for 2022 was -233.73%, a 39.44% increase from 2021.
  • Cytokinetics average ebitda margin for 2021 was -385.97%, a 14.62% decline from 2020.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Cytokinetics EBITDA Margin 2010-2024 | CYTK

  • Cytokinetics average ebitda margin for 2023 was -4208.97%, a 1700.78% increase from 2022.
  • Cytokinetics average ebitda margin for 2022 was -233.73%, a 39.44% increase from 2021.
  • Cytokinetics average ebitda margin for 2021 was -385.97%, a 14.62% decline from 2020.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.8B
Vertex Pharmaceuticals (VRTX)$117.5B
Regeneron Pharmaceuticals (REGN)$111.6B
Bristol Myers Squibb (BMY)$109.4B
Gilead Sciences (GILD)$105.3B
CSL (CSLLY)$95.7B
GSK (GSK)$80.5B
Alnylam Pharmaceuticals (ALNY)$34.4B
Argenex SE (ARGX)$31.7B
BioNTech SE (BNTX)$29.2B
Biogen (BIIB)$27B
BeiGene (BGNE)$23.9B
Moderna (MRNA)$23.1B
Illumina (ILMN)$22.5B
Genmab (GMAB)$15.5B
BioMarin Pharmaceutical (BMRN)$13.2B
Incyte (INCY)$13B
Exact Sciences (EXAS)$12.6B
Vaxcyte (PCVX)$12.4B
Insmed (INSM)$12.4B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.5B
QIAGEN (QGEN)$9.9B
Bio-Rad Laboratories (BIO.B)$9.3B
Legend Biotech (LEGN)$8.9B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$8.3B
Revolution Medicines (RVMD)$7.9B
Intra-Cellular Therapies (ITCI)$7.7B
Repligen (RGEN)$7.7B